NuVasive, Inc. is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is product portfolio is focused on applications for spine fusion surgery, including biologics. Its principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS). The product platform includes its software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system, and a variety of specialized implants. Its biologic product line offerings used to aid the spinal fusion process or bone healing include allograft (donated human tissue), Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells, or MSCs, FormaGraft, a collagen synthetic product, and AttraX, a synthetic bone graft material.